Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 amp |
Therapy | Nivolumab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 amp | lung non-small cell carcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical case study, a CD274 (PD-L1) amplified non-small cell lung carcinoma patient treated with Opdivo (nivolumab) achieved stable disease with a 20% reduction in tumor growth and a progression-free survival of 9.7 months (PMID: 32955570). | 32955570 |
CD274 amp | lung non-small cell carcinoma | predicted - sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, treatment with Opdivo (nivolumab) did not result in a significant overall response rate (ORR) in non-small cell lung cancer (NSCLC) patients with a CD274 copy number gain (CNG; amplification and polysomy) vs patients without a CNG (28.1% vs. 17.9%; p=0.22), but NSCLC patients with CD274 amplification demonstrated an ORR of 80% (4/5), a 1-year progression-free survival of 80%, a 1-year overall survival of 100%, and the median duration of response was not yet reached (PMID: 32955570). | 32955570 |
PubMed Id | Reference Title | Details |
---|---|---|
(32955570) | Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer. | Full reference... |
(32955570) | Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer. | Full reference... |